Sanofi’s Sarclisa Granted FDA Priority Review For Transplant-Ineligible Multiple Myeloma Treatment
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Sanofi – Aventis Groupe said that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa or isatuximab in combination with bortezomib, lenalidomide and dexame
:max_bytes(150000):strip_icc():format(jpeg)/business-team-investment-entrepreneur-trading-discussing-and-analysis-graph-stock-market-trading-stock-chart-concept-1089940388-acef8549576a4d918cb157c6c88ec8a1.jpg "Introduction to Phantom Stocks and SARs")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-991180154-aad62bea33e2473a808a24eb81b8e068.jpg "How the Minimum Wage Impacts Unemployment")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1427847593-c401663a1b954137ac712a650eea3a95.jpg "Borrowing from Your Retirement Plan")
